Richard Stratton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3807568/publications.pdf Version: 2024-02-01



RICHARD STRATTON

#	Article	IF	CITATIONS
1	lloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. Journal of Clinical Investigation, 2001, 108, 241-250.	8.2	178
2	A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS ONE, 2015, 10, e0126015.	2.5	77
3	Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFÎ ² Signaling within Lesional Scleroderma Skin. PLoS ONE, 2015, 10, e0134092.	2.5	61
4	Autoimmunity and HIV. Current Opinion in Infectious Diseases, 2009, 22, 49-56.	3.1	47
5	Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis. Journal of Cellular and Molecular Medicine, 2020, 24, 14026-14038.	3.6	39
6	The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Research and Therapy, 2018, 20, 152.	3.5	36
7	Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology, 2020, 59, 2625-2636.	1.9	33
8	Combining nano-physical and computational investigations to understand the nature of "aging" in dermal collagen. International Journal of Nanomedicine, 2017, Volume 12, 3303-3314.	6.7	26
9	Role of prostaglandins in fibroblast activation and fibrosis. Journal of Cell Communication and Signaling, 2010, 4, 75-77.	3.4	25
10	Pathogenic Activation of Mesenchymal Stem Cells Is Induced by the Disease Microenvironment in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1361-1374.	5.6	23
11	Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis. Rheumatology, 2019, 58, 527-535.	1.9	22
12	Quantitative nanohistological investigation of scleroderma: an atomic force microscopy-based approach to disease characterization. International Journal of Nanomedicine, 2017, Volume 12, 411-420.	6.7	15
13	Chemokines in systemic sclerosis. Immunology Letters, 2018, 195, 68-75.	2.5	14
14	Wnt antagonist DKK″ levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33aâ€3p. Experimental Dermatology, 2021, 30, 162-168.	2.9	13
15	Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis. Frontiers in Cell and Developmental Biology, 2021, 9, 681061.	3.7	13
16	microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis. Epigenetics, 2021, 16, 808-817.	2.7	12
17	Appearance of Florid Cemento-Osseous Dysplasia on SPECT/CT. Clinical Nuclear Medicine, 2019, 44, e357-e359.	1.3	9
18	Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration. Scientific Reports, 2017, 7, 2628.	3.3	4

RICHARD STRATTON

#	Article	IF	CITATIONS
19	Images of the month 3: An unusual case of a red painful eye. Clinical Medicine, 2020, 20, 114-114.	1.9	4
20	Commentary on a recent article—"A prostacyclin analogue, lloprost, protects from bleomycin-induced fibrosis in mice―Zhu Y et al. Respir Res. 2010 Mar 20;11(1):34. Journal of Cell Communication and Signaling, 2010, 4, 187-188.	3.4	3
21	P21â€fMy eye was cloudy at first and I can see it is melting away!. Rheumatology Advances in Practice, 2021, 5, .	0.7	2
22	E96.â \in fIntravenous Immunoglobulin in Refractory Polyarteritis Nodosa. Rheumatology, O, , .	1.9	0
23	O17â€∫Interleukin 31 promotes pathogenic mechanisms in scleroderma and induces skin fibrosis in mice. Rheumatology, 2018, 57, .	1.9	0
24	78. Atypical presentation of anti-signal recognition particle antibody positive myositis with profound extra-muscular features. Rheumatology Advances in Practice, 2018, 2, .	0.7	0
25	024 Thick and fast: two cases of eosinophilic fasciitis. Rheumatology, 2018, 57, .	1.9	0
26	14.â $∈$ fA great mimicking vasculitis. Rheumatology Advances in Practice, 2018, 2, .	0.7	0
27	198 Critical role of the prolyl 3-hydroxylase LEPREL1 in scleroderma-related fibrosis. Rheumatology, 2018, 57, .	1.9	0
28	007 Immunoglobulin G4 related disease with isolated pulmonary involvement in a patient with seropositive rheumatoid arthritis taking adalimumab. Rheumatology, 2018, 57, .	1.9	0
29	O06 Prolyl 3-hydroxylase 2 is a candidate gene in scleroderma involved in collagen synthesis and fibrosis. Rheumatology, 2019, 58, .	1.9	0
30	130â€fAtaxic neuropathy in Sjögren's syndrome. Rheumatology, 2019, 58, .	1.9	0
31	SAT0436â€CROWNED-DENS SYNDROME: A RECENT CASE SERIES IN A SINGLE CENTRE IN THE UNITED KINGDC , 2019, , .	DM.	0
32	P168 Modelling macrophage-fibroblast interaction in scleroderma to evaluate new treatments. Rheumatology, 2020, 59, .	1.9	0
33	P29 Use of novel biologic therapies for arthropathy affecting common variable immunodeficiency patients. Rheumatology, 2020, 59, .	1.9	0
34	Ochronotic arthropathy in alkaptonuria. Rheumatology, 2021, 60, 2486-2486.	1.9	0
35	P105 Auto-inflammatory idiopathic serositis: an under-characterised phenomenon?. Rheumatology, 2021, 60, .	1.9	0
36	COVID-19 in Northeast Bosnia and Herzegovina and patient's length of hospitalization. BMC Infectious Diseases, 2021, 21, 367.	2.9	0

#	Article	IF	CITATIONS
37	P104 A review of patients referred to Rheumatology with haemophagocytic lymphohistiocytosis who were treated with anakinra successfully. Rheumatology, 2021, 60, .	1.9	Ο